Literature DB >> 12084597

Differential effects of beta-blockade on dispersion of repolarization in the absence and presence of sympathetic stimulation between the LQT1 and LQT2 forms of congenital long QT syndrome.

Wataru Shimizu1, Yasuko Tanabe, Takeshi Aiba, Masashi Inagaki, Takashi Kurita, Kazuhiro Suyama, Noritoshi Nagaya, Atsushi Taguchi, Naohiko Aihara, Kenji Sunagawa, Kazufumi Nakamura, Tohru Ohe, Jeffrey A Towbin, Silvia G Priori, Shiro Kamakura.   

Abstract

OBJECTIVES: This study compared the effects of beta-blockade on transmural and spatial dispersion of repolarization (TDR and SDR, respectively) between the LQT1 and LQT2 forms of congenital long QT syndrome (LQTS).
BACKGROUND: The LQT1 form is more sensitive to sympathetic stimulation and more responsive to beta-blockers than either the LQT2 or LQT3 forms.
METHODS: Eighty-seven-lead, body-surface electrocardiograms (ECGs) were recorded before and after epinephrine infusion (0.1 microg/kg body weight per min) in the absence and presence of oral propranolol (0.5-2.0 mg/kg per day) in 11 LQT1 patients and 11 LQT2 patients. The Q-T(end) interval, the Q-T(peak) interval and the interval between T(peak) and T(end) (T(p-e)), representing TDR, were measured and averaged from 87-lead ECGs and corrected by Bazett's method (corrected Q-T(end) interval [cQT(e)], corrected Q-T(peak) interval [cQT(p)] and corrected interval between T(peak) and T(end) [cT(p-e)]). The dispersion of cQT(e) (cQT(e)-D) was obtained among 87 leads and was defined as the interval between the maximum and minimum values of cQT(e).
RESULTS: Propranolol in the absence of epinephrine significantly prolonged the mean cQT(p) value but not the mean cQT(e) value, thus decreasing the mean cT(p-e) value in both LQT1 and LQT2 patients; the differences with propranolol were significantly larger in LQT1 than in LQT2 (p < 0.05). The maximum cQT(e), minimum cQT(e) and cQT(e)-D were not changed with propranolol. Propranolol completely suppressed the influence of epinephrine in prolonging the mean cQT(e), maximum cQT(e) and minimum cQT(e) values, as well as increasing the mean cT(p-e) and cQT(e)-D values in both groups.
CONCLUSIONS: Beta-blockade under normal sympathetic tone produces a greater decrease in TDR in the LQT1 form than in the LQT2 form, explaining the superior effectiveness of beta-blockers in LQT1 versus LQT2. Beta-blockers also suppress the influence of sympathetic stimulation in increasing TDR and SDR equally in LQT1 and LQT2 syndrome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12084597     DOI: 10.1016/s0735-1097(02)01894-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  16 in total

1.  β-blockers protect against dispersion of repolarization during exercise in congenital long-QT syndrome type 1.

Authors:  Lee W Gemma; Gregory M Ward; Mary M Dettmer; Jennifer L Ball; Peter J Leo; Danielle N Doria; Elizabeth S Kaufman
Journal:  J Cardiovasc Electrophysiol       Date:  2011-06-02

Review 2.  Potential proarrhythmic effects of biventricular pacing.

Authors:  Jeffrey M Fish; Josep Brugada; Charles Antzelevitch
Journal:  J Am Coll Cardiol       Date:  2005-12-20       Impact factor: 24.094

Review 3.  The risk of cardiac events and genotype-based management of LQTS patients.

Authors:  Grazyna Markiewicz-Łoskot; Ewa Moric-Janiszewska; Urszula Mazurek
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-01       Impact factor: 1.468

Review 4.  Genotype- and phenotype-guided management of congenital long QT syndrome.

Authors:  John R Giudicessi; Michael J Ackerman
Journal:  Curr Probl Cardiol       Date:  2013-10       Impact factor: 5.200

5.  Cellular basis for electrocardiographic and arrhythmic manifestations of Andersen-Tawil syndrome (LQT7).

Authors:  Masato Tsuboi; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2006-03       Impact factor: 6.343

6.  Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy.

Authors:  Kazunobu Kawakami; Toshihisa Nagatomo; Haruhiko Abe; Kan Kikuchi; Hiroko Takemasa; Blake D Anson; Brian P Delisle; Craig T January; Yasuhide Nakashima
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

Review 7.  Specific therapy based on the genotype and cellular mechanism in inherited cardiac arrhythmias. Long QT syndrome and Brugada syndrome.

Authors:  Wataru Shimizu; Takeshi Aiba; Charles Antzelevitch
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

8.  Long QT syndrome: A therapeutic challenge.

Authors:  Maully Shah; Christopher Carter
Journal:  Ann Pediatr Cardiol       Date:  2008-01

9.  The role of acute hyperinsulinemia in the development of cardiac arrhythmias.

Authors:  László Drimba; Róbert Döbrönte; Csaba Hegedüs; Réka Sári; Yin Di; Joseph Németh; Zoltán Szilvássy; Barna Peitl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-03-10       Impact factor: 3.000

Review 10.  Pharmacological approach to the treatment of long and short QT syndromes.

Authors:  Chinmay Patel; Charles Antzelevitch
Journal:  Pharmacol Ther       Date:  2008-04       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.